127.90 USD
-1.38
1.07%
At close Jul 29, 4:00 PM EDT
After hours
127.23
-0.67
0.52%
1 day
-1.07%
5 days
-1.19%
1 month
1.84%
3 months
6.43%
6 months
-11.43%
Year to date
-14.73%
1 year
-40.35%
5 years
-53.89%
10 years
-59.18%
 

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,605

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

24% more repeat investments, than reductions

Existing positions increased: 325 | Existing positions reduced: 263

22% more first-time investments, than exits

New positions opened: 127 | Existing positions closed: 104

1% more funds holding

Funds holding: 855 [Q4 2024] → 863 (+8) [Q1 2025]

3.4% less ownership

Funds ownership: 90.14% [Q4 2024] → 86.74% (-3.4%) [Q1 2025]

14% less capital invested

Capital invested by funds: $20.1B [Q4 2024] → $17.4B (-$2.72B) [Q1 2025]

44% less call options, than puts

Call options by funds: $345M | Put options by funds: $621M

50% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$115
10%
downside
Avg. target
$182
42%
upside
High target
$255
99%
upside

8 analyst ratings

positive
63%
neutral
38%
negative
0%
RBC Capital
Brian Abrahams
67%upside
$213
Outperform
Reiterated
27 Jun 2025
HC Wainwright & Co.
Andrew Fein
46%upside
$187
Buy
Reiterated
26 Jun 2025
Piper Sandler
David Amsellem
10%downside
$115
Neutral
Reiterated
12 Jun 2025
Wedbush
Laura Chico
5%downside
$121
Neutral
Reiterated
12 Jun 2025
Mizuho
Salim Syed
32%upside
$169
Outperform
Maintained
7 May 2025

Financial journalist opinion

Based on 11 articles about BIIB published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Neutral
GlobeNewsWire
4 days ago
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023.
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
Negative
Zacks Investment Research
5 days ago
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Neutral
GlobeNewsWire
1 week ago
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Positive
Benzinga
1 week ago
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Biogen Inc.  BIIB said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP).
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Positive
Reuters
1 week ago
Biogen to invest $2 billion more in North Carolina
Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
Biogen to invest $2 billion more in North Carolina
Neutral
GlobeNewsWire
1 week ago
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP). Since breaking ground in 1995, Biogen's manufacturing in RTP has played a vital role in delivering the company's pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen's late-stage clinical pipeline.
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
Neutral
Business Wire
2 weeks ago
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a.
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Neutral
GlobeNewsWire
2 weeks ago
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass.
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Negative
Zacks Investment Research
4 weeks ago
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
Charts implemented using Lightweight Charts™